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Prostate-specific membrane antigen (PSMA) or folate hydrolase 1 (FOLH1) is highly expressed on prostate cancer. Its expression correlates inversely with survival and increases with tumor grade. However, the biological role of PSMA has not
been explored, and its role in prostate cancer remained elusive. Filling this gap, we demonstrate that in prostate cancer,
PSMA initiates signaling upstream of PI3K through G protein–coupled receptors, specifically via the metabotropic glutamate receptor (mGluR). PSMA’s carboxypeptidase activity releases glutamate from vitamin B9 and other glutamated substrates, which activate mGluR I. Activated mGluR I subsequently induces activation of phosphoinositide 3-kinase (PI3K)
through phosphorylation of p110β independent of PTEN loss. The p110β isoform of PI3K plays a particularly important role
in the pathogenesis of prostate cancer, but the origin of its activation was so far unknown. PSMA expression correlated with
PI3K–Akt signaling in cells, animal models, and patients. We interrogated the activity of the PSMA–PI3K axis through positron emission tomography and magnetic resonance imaging. Inhibition of PSMA in preclinical models inhibited PI3K signaling and promoted tumor regression. Our data present a novel oncogenic signaling role of PSMA that can be exploited for
therapy and interrogated with imaging.

Introduction
Prostate cancer is the most common cancer diagnosed in
men. It is estimated that one in every seven men will be diagnosed with the disease during his lifetime. Although the
medical community utilizes early diagnostic tools and new
therapeutic approaches for localized disease, the National
Institutes of Health’s Surveillance, Epidemiology, and End
Results Program (SEER) estimates that 26,730 deaths will
be attributed to metastatic prostate cancer in 2017. Molecular hallmarks of prostate cancer include aberrant signaling of the androgen receptor (AR) and phosphoinositide
3-kinase (PI3K) pathways (Ferté et al., 2010; Perner et al.,
2015), as well as expression of prostate-specific membrane
antigen (PSMA; Sweat et al., 1998). In fact, PSMA (also
known as folate hydrolase 1 [FOLH1] or glutamate carboxypeptidase II [GCP
II]; EC number 3.4.17.21; gene
symbol FOLH1; gene ID 2346) is the most prominent prosCorrespondence to Jan Grimm: grimmj@mskcc.org
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tate cancer cell-surface biomarker and is also found in the
neovasculature of solid tumors (Chang et al., 1999). PSMA
(FOLH1, GCPII) is normally expressed in the proximal
renal tubules and duodenum, where it plays a major role
in the processing and uptake of dietary folates, and in the
brain, where it processes N-acetyl-l-aspartyl-l-glutamate
(NAAG) to modulate the output of glutamate signaling transduced via the metabotropic glutamate receptor
(mGluR) pathway (Rajasekaran et al., 2005; Rahn et al.,
2012a). PSMA has been successfully used for the imaging
of primary and metastatic prostate cancer in patients with
radiolabeled PSMA-targeting antibodies or, more recently,
small molecules (Pandit-Taskar et al., 2015; Maurer et al.,
2016). PSMA-targeted radiotherapy in metastatic castration-resistant prostate cancer was recently able to confer
© 2018 Kaittanis et al. This article is distributed under the terms of an Attribution–Noncommercial–Share
Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org
/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–
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Results
Expression of PSMA in patients with prostate cancer
correlates with elevated mTOR signaling
Because PSMA (FOLH1) has been identified as a promising marker for prostate cancer, we investigated whether its
expression is reflective of disease state in cancer patients. We
first analyzed genomic data obtained from prostate cancer patients with localized disease at our institution, and we found
that higher PSMA expression was positively associated with
faster biochemical recurrence (Fig. 1 A and Table S1) and
metastasis (Fig. 1 B and Table S2). Given the clear correlation
of PSMA with disease aggressiveness, we examined whether
overexpression of PSMA correlates with alterations in major
oncogenic signaling pathways. Immunohistochemical analysis of tissue microarray samples of prostate cancer patients
showed that increased PSMA levels are indeed associated with
the phosphorylation of 4EBP1, a downstream target of the
mammalian target of rapamycin (mTOR; Fig. 1 C). Subsequent gene set enrichment analysis of patients’ genomics data
further corroborated the histopathological findings, revealing
that PSMA levels are associated with changes in the transcriptional levels of mTOR-regulated genes (Fig. 1 D). Collectively, these observations in clinical samples of prostate cancer
prompted us to further elucidate a possible PSMA-induced
signaling mechanism, which may provide novel personalized
therapeutic interventions with improved disease management
through PSMA-targeted PET imaging.
PSMA promotes downstream Akt signaling
in prostate cancer
Intrigued by the clinical findings, we next examined whether
PSMA expression in prostate cancer cell lines has any effect
on the Akt–mTOR signaling cascade. To achieve this, we
used human prostate cancer cell lines, which either expressed
(LNCaP-Ctrl and PC3-PSMA) or lacked PSMA (LNCaPKD and PC3-Ctrl; Fig. S1, A–C). Gene set enrichment analysis revealed that in cells expressing PSMA, the levels of genes
involved and regulated by Akt and mTOR were elevated
(Fig. 2 A), similar to what was observed in patients, indicating
that PSMA modulates the activity of the Akt–mTOR cascade in prostate cancer.
Because the PSMA protein itself does not carry any signaling-relevant moieties, we then focused on its enzymatic
function as a glutamate carboxypeptidase. In the brain, PSMA
modulates neuronal signaling within the synaptic cleft by
hydrolyzing the amide bond that links the glutamate moiety with N-acetylaspartate of the neurotransmitter NAAG.
The released glutamate then activates postsynaptic metabotropic glutamate receptors, leading to mobilization of calcium within the postsynaptic neuron (Fig. 2 B). We reasoned
that a similar mechanism might be at play in prostate cancer
cells as well. Specifically, we examined whether similar to its
function in the brain PSMA’s enzymatic release of glutamate
could activate mGluR to facilitate activation of the PI3K–
Akt–mTOR axis. Because PSMA is known to hydrolyze folic
PSMA activates PI3K–Akt signaling via mGluR I | Kaittanis et al.
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improved biochemical and radiological response, with sustained decline in prostate-specific antigen (PSA) levels and
decreased lesion number and size (Kratochwil et al., 2016;
Rahbar et al., 2017). In spite of the significant interest in
PSMA as a target for imaging and therapy, the biological
role of PSMA in prostate cancer remained elusive. Although
previous studies showed that PSMA confers an advantage
to prostate cancer cells through the processing of polyglutamated folates to folic acid and additionally affects the
expression of proinflammatory cytokines (Yao and Bacich,
2006; Colombatti et al., 2009), an exact mechanism explaining a biological function of PSMA in prostate cancer
was until now not known. In this work, we demonstrate
that PSMA activates PI3K–Akt signaling in prostate cancer
through release of glutamate as messenger molecule.
In addition to using PSMA as a structural anchor for
targeted radiotherapeutics or experimental drugs (Hrkach
et al., 2012), the primary clinical management of prostate
cancer is currently based on therapeutic interventions that
target the AR cascade, including androgen deprivation, antiandrogens, and neoadjuvant chemotherapy (Mitsiades,
2013). Unfortunately, patients almost always stop responding
to AR inhibitors within 6 to 12 mo and progress to castration-resistant prostate cancer (Yuan et al., 2014). Genomic
studies revealed that 40% of primary and 70% of metastatic
prostate cancer patients have alterations in the PI3K signaling axis, including loss of PTEN, which along with the AR
support survival signals in the disease (El Sheikh et al., 2008;
Reid et al., 2010; Taylor et al., 2010). Particularly, it was
shown that PI3K signaling in prostate cancer depends predominantly on PI3K’s p110β isoform (Jia et al., 2008; Jiang
et al., 2010). However, the mechanism of p110β activation
in prostate cancer remained so far unknown (Schwartz et
al., 2015). Efforts to elucidate this key mechanism demonstrated p110β activation by a G protein–coupled receptor
(GPCR; Cizmecioglu et al., 2016), but the exact GPCR
remained unknown. In our work, we show that PSMA activates a GPCR (mGluR I) through release of glutamate.
Up-regulation of mGluR’s expression has been identified
in several malignancies, including prostate cancer (Yu et al.,
2017). The findings of this study propose the use of PSMA
as a surrogate marker for the activity of the PI3K signaling
axis, which can be interrogated through molecular imaging
with positron emission tomography (PET) imaging.
Combination therapies that block AR and PI3K pathways have been proposed. However, therapy with PI3K inhibitors in a disease-specific fashion has been challenging
because of toxicity issues associated with off-tumor side effects from suppression of PI3K signaling in healthy organs
(Dienstmann et al., 2014). In this work, we demonstrate that
PSMA activates PI3K–Akt signaling in prostate cancer and
demonstrate a new combination therapy in the inhibition
of AR and PSMA as an alternative, tumor-selective strategy
for PI3K signaling suppression to avoid PI3K inhibition in
healthy tissues that lack PSMA expression.

acids (Yao et al., 2008), we replaced NAAG for folic acid (vitamin B9) as PSMA substrate, because vitamin B9 is ubiquitous in the body.Toward this direction, we first confirmed the
transcriptomic findings by assessing the phosphorylation levels of Akt and its downstream targets. Indeed, we found that
expression of PSMA increased the phosphorylation of Akt
and its downstream targets S6K and 4EBP1, whereas ablation
of PSMA expression had the opposite effect (Fig. 2, C–F).
Inhibition of PSMA’s enzymatic activity with the highly selective inhibitor 2-PMPA (Zhou et al., 2005; Ki = 275 pM)
resulted in a decrease in phosphorylation (Fig. 2 G), which
was comparable to suppression of PSMA expression. Having demonstrated that PSMA activates Akt–mTOR signaling
through its enzymatic activity, we next determined whether
PSMA could be a bona fide modulator of oncogenic signaling in prostate cancer. Therefore, we engineered PC3 cells
to express enzymatically active PSMA (PC3-PSMAwt), and
JEM Vol. 215, No. 1

implanted them in male, athymic nude mice. Immunohistochemistry on slices from mouse xenografts showed that expression of wild-type PSMA was associated with elevated Akt
phosphorylation (Fig. 3 A and Fig. S1, D–G), which was in
line with our in vitro studies and clinical findings. These data
show that PSMA expression in prostate cancer up-regulates
the Akt–mTOR signaling pathway and is mediated through
PSMA’s enzymatic activity.
PSMA controls the phosphorylation of p110β,
but not p110α or p110δ
As the PI3K-p110β isoform is particularly implicated in
prostate cancer (Jia et al., 2008; Jiang et al., 2010), and because p110β is probably activated by a yet-unknown GPCR
(Cizmecioglu et al., 2016), we hypothesized that glutamate
released by PSMA may activate PI3K in an isoform-specific
mode through the GPCRs of the mGluR I group. To test
161
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Figure 1. Expression of PSMA in patients is associated with activated Akt. (A and B) Elevated PSMA expression is associated with disease relapse (A)
and metastases (B) in prostate cancer (MSKCC cohort PMID 25024180). High PSMA expression is defined as expression z-score >2, and low PSMA expression is defined as z-score ≤ 2. (C) Immunohistochemistry on representative samples from prostate cancer patients shows that enhanced PSMA expression
correlates with elevated phosphorylation of the Akt target 4EBP1. (D) Gene set enrichment analysis comparing prostate cancer patients with normal PSMA
levels with prostate cancer patients with high (z-score >2) PSMA levels. The dataset from the MSKCC prostate cancer cohort (PMID 25024180) was used.
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Figure 2. Expression of enzymatically active PSMA up-regulates the Akt–mTOR pathway. (A) PSMA-expressing cells are associated with enrichment
of Akt and mTOR signaling signatures. Gene set enrichment analysis comparing PSMA-expressing cells (LNCaP-Ctrl) with their PSMA-negative counterparts
(LNCaP-KD). The gene set data were derived from the mean of three independent experiments obtained through the Affymetrix platform. (B) In the brain,
PSMA, encoded by the FOLH1 gene and termed glutamate carboxypeptidase II (GCP-II), modulates glutamatergic neurotransmission via activation of postsynaptic metabotropic glutamate receptor (mGluR) system through the proteolytic cleavage of the amide bond of NAAG. (C–E) Increased phosphorylation
of Akt, S6, and 4EBP1 in PSMA-expressing cells was determined with immunoblot analysis. Relative intensities normalized to actin levels (n = 3). (F and G)
Expression of enzymatically active PSMA leads to phosphorylation of Akt, mTOR, and S6, as determined through a reverse-phase protein array (R&D Systems, Inc.). Changes in phosphorylation calculated as deviations from the control cell line (LNCaP-Ctrl for the PSMA knockdown cells [LNCaP-KD], PC3-Ctrl
for PC3-PSMA that overexpress PSMA, and LNCaP-Ctrl for LNCaP-Ctrl cells that were treated for 2 h with the PSMA inhibitor 2-PMPA; n = 4 per condition).
Graphs show mean ± SEM. **, P < 0.01 (unpaired t test).

this, we used a clinically translational proteomics platform
with high-throughput capabilities that utilizes as few as 25
cells and examines the global phosphorylation status of the
protein of interest through changes of the proteins isoelectric point (NanoPro 1000; Protein Simple). We identified
that inhibition of PSMA’s enzymatic activity impaired phosphorylation of PI3K-p110β, but not the p110α and p110δ
162

isoforms (Fig. 3 B). Importantly, control treatment with an
mGluR I agonist resulted in phosphorylation of p110β only
similar to activation by PSMA in the presence of glutamated
folate. Control studies corroborated that inhibition of p110β
in prostate cancer decreased the phosphorylation of Akt
(Fig. 3 C and Fig. S2 A), whereas glutamated folate did not
alter the activation of Akt in cells lacking PSMA (Fig. S2 B).
PSMA activates PI3K–Akt signaling via mGluR I | Kaittanis et al.

To further confirm that PSMA specifically activates
p110β in prostate cancer, we used an Akt-specific fluorescent substrate that emits at 700 nm once phosphorylated
by Akt (Shen et al., 2013) and observed that inhibition of
PSMA, mGluR I, or p110β equally suppressed Akt activation (Fig. 3 D). Through a reverse-phase protein array, we
observed that inhibition of PSMA’s enzymatic activity in
PSMA-expressing cells decreased Akt activation but had no
effect in cells lacking PSMA (LNCaP-KD and PC3-Ctrl;
Fig. 3 E). Next, in order to corroborate that it really is the
enzymatic activity of PSMA that induces the signaling casJEM Vol. 215, No. 1

cade, we created cells that expressed enzymatically inactive
PSMA (PC3-PSMAmut). In these cells glutamated folate did
not induce activation of Akt or its downstream targets, such
as PRAS40 (Fig. S2, C–E). We also determined that in prostate cancer cells that have wild-type, functional PTEN and
express PSMA (22Rv1), treatment with glutamate folate induced activation of Akt, similar to PSMA-expressing cells that
do not express PTEN (LNCaP; Fig. S2, F–K). Furthermore,
inhibition of PSMA decreased the activity of the Akt-target
epithelial nitric oxide synthase and increased that of the AR,
as reflected in higher levels of the PSA (Fig. S2, L and M).
163
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Figure 3. PSMA up-regulates Akt through activation of PI3K-p110β via mGluR I. (A) Immunohistochemistry of PC3-Ctrl and PC3-PSMA tumors
grown on male, athymic nude mice shows elevated Akt1 phosphorylation in the PSMA-expressing tumors. Representative images of slices fixed in paraffin
and stained with anti–human PSMA, pan-Akt, and phospho-Akt1 antibodies (bars, 100 µm). (B) Global changes in the phosphorylation status of components
of the PI3K pathway were determined with the NanoPro 1000 system (Protein Simple). NanoPro-based analysis of PI3K’s catalytic subunits in LNCaP-Ctrl
cells following 2 h stimulation with monoglutamated folate (Glu-Fol) or an mGluR I agonist (L-Quisqualic acid; PSMA inhibitor: 2-PMPA) in basal medium
deprived of serum, folate and glutamate, showing that PSMA facilitates the phosphorylation of PI3K-p110β though activation of mGluR I. Before stimulation, the cells were starved for 24 h in basal medium. Phosphorylation alterations were calculated as the difference observed between the treatment group
and unstimulated cells (n = 3 per condition). (C) Inhibition of PI3K-p110β suppresses Akt activation, similar to PSMA and mGluR I inhibition in prostate
cancer. LNCaP-Ctrl cells were treated with Glu-Fol and inhibitors for 2 h. Phosphorylation was assessed through a reverse-phase protein array (n = 3 per
treatment). (D) The fluorescent Akt-specific substrate LS456, whose fluorescence emission shifts from emission in the near-infrared range (λ = 800 nm) to
the red sector of the visible light (λ = 700 nm) upon phosphorylation by the kinase, was used to assess Akt activation by PSMA. LNCaP-Ctrl cells were treated
with Glu-Fol and pharmacological agents for 2 h, as described above for panel B of this figure (n = 12 per treatment). (E) Inhibition of PSMA’s enzymatic
activity with 2-PMPA decreases Akt’s phosphorylation in PSMA-expressing cells. Cells were grown in complete medium and treated for 2 h with 2-PMPA.
Control cells were treated with 1× PBS. Changes in Akt’s phosphorylation were determined with a reverse-phase protein array (n = 3 per treatment). Graphs
show mean ± SEM. ns, not significant; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001 (ordinary one-way ANOVA).

This is in line with previous work that demonstrated that
inhibition of PI3K releases inhibition of the AR, and vice
versa (Carver et al., 2011). Because of the elevated activity
of Akt and epithelial nitric oxide synthase, it is likely possible that the higher levels of Akt protein in PSMA-expressing
tumors (Fig. 3 A and Fig. S1 E) might be due to nitric oxide
up-regulating the transcription factor RUNX2, which regulates expression of Akt, in a reciprocal feedback loop in prostate cancer (Cohen-Solal et al., 2015; Nesbitt et al., 2016).
Collectively, these data demonstrate that through its ability
to hydrolyze glutamated folates, PSMA facilitates activation
of PI3K-p110β and Akt via mGluR I, thus promoting oncogenic signaling in prostate cancer. Collectively, these data
show that PSMA activates p110β through enzymatic release
of glutamate from folic acid.
PSMA activates mGluR I through the release of glutamate
After showing that PSMA initiates p110β-dependent PI3K
signaling via mGluR I as a result of its enzymatic release of glutamate from glutamated folate, we further evaluated the consequences of PSMA-mediated activation of the GPCR mGluR I.
Outside the central nervous system, such as in the duodenum,
PSMA similarly releases free glutamate from glutamated folates
through its zinc metalloproteinase catalytic mechanism (Klusák
et al., 2009).We therefore showed that exogenous supplementation of the culture medium with either free glutamate or
glutamated folate and recombinant PSMA activated Akt in a
p110β-specific mode in PSMA-negative cells (Fig. 4 A).
Because PSMA regulates calcium levels in the brain
through the release of glutamate, we reasoned that PSMA
164

could also regulate calcium-mediated signaling in prostate
cancer. Hence, we examined whether PSMA’s processing of
glutamated folates had an impact on phospholipase C activation and cytoplasmic calcium levels in prostate cancer. In line
with our proposed mechanism, elevation of cytoplasmic calcium was observed in PSMA-expressing cells in the presence
of glutamated folates in a dose-dependent pattern (Fig. S3,
A–C). Supplementation of PSMA-null cells with glutamated
folate and recombinant PSMA caused calcium increase in
the cytoplasm, which was inhibited in the presence of either
2-PMPA or the mGluR I antagonist (Fig. 4 B).
In PSMA-expressing cells, treatment with an mGluR
I antagonist, phospholipase C inhibitor, or 2-PMPA abrogated the PSMA-mediated calcium influx to the cytoplasm,
whereas mGluR I agonists potentiated it (Fig. S3 D). These
findings indicate that PSMA-triggered mGluR I activation
also leads to phospholipase C activation and downstream
activation of inositol trisphosphate receptors that release
calcium from the endoplasmic reticulum to the cytoplasm.
Because apart from mGluR I, calcium levels can be also
modulated by NMDA and AMPA receptors, we treated
PSMA-expressing cells with inhibitors of these receptors.We
found that treatment with these compounds did not have any
effect on calcium levels in the presence of glutamated folate
(Fig. S3 E), demonstrating that mGluR I is activated by free
glutamate released by PSMA at the plasma membrane of
prostate cancer cells. Because treatment with an mGluR I agonist caused calcium mobilization in cells lacking PSMA, this
showed that the glutamatergic system was functional in these
cells (Fig. S3 F). As cells expressing PSMA had also higher
PSMA activates PI3K–Akt signaling via mGluR I | Kaittanis et al.
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Figure 4. Released glutamate from PSMA-processed glutamate folate activates mGluR I and up-regulates cytoplasmic calcium levels. (A) PSMA
activates Akt in a p110b-dependent fashion, using glutamate as the molecular messenger. PC3-Ctrl cells grown on 96-well plates were supplemented with
Glu-Fol, recombinant PSMA, and inhibitors for 2 h. The change in 700-nm fluorescence intensity emission of the Akt-specific substrate LS456 was calculated
based on unstimulated cells (n = 12 per treatment). (B) The released glutamate by PSMA engages mGluR I, mobilizing calcium to the cytoplasm. PC3-Ctrl
cells were incubated in basal medium deprived of serum, folate, and glutamate for 4 h at 37°C, 5% CO2 (mGluR I agonist: (S)-3,5,-DHPG; n = 8 per condition). Detection was achieved with the Fluo-4 Direct calcium kit. (C) Intracellular calcium levels upon stimulation of cells expressing wild-type (PSMAwt) and
enzymatically inactive PSMA (PSMAmut). Changes in [Ca2+] were calculated with respect to nonstimulated PC3-PSMAwt or PC3-PSMAmut cells grown in basal
RPMI medium, as mentioned above for panel B of this figure (mGluR I agonist: (S)-3,5,-DHPG; n = 8 per condition). Graphs show mean ± SEM. *, P < 0.05,
***, P < 0.001; ****, P < 0.0001 (ordinary one-way ANOVA).

Figure 5. Inhibition of PSMA improves
response to chemotherapy in vitro. (A–D)
Inhibition of FOLH’s enzymatic activity and
PI3K-p110β reduces the viability of PSMAexpressing prostate cancer cells. Cells were
treated with PI3K inhibitors (Pan: BKM120;
PI3Kα: BYL719; PI3Kβ: GSK2636771; [inhibitor]
= 200 nM) and 2-PMPA (200 nM) for 48 h at
37°C, 5% CO2 (n = 12 per treatment). Viability
was determined with the Alamar blue assay.
Graphs show means ± SEM. ns, not significant; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001
(ordinary one-way ANOVA).

JEM Vol. 215, No. 1

Inhibition of PSMA in vivo confers a therapeutic advantage
Having demonstrated that expression of PSMA in prostate
cancer patients is associated with Akt activation and faster
disease progression and that PSMA through its enzymatic
activity activates the PI3K–Akt axis, we next evaluated
whether targeting of PSMA could serve as potential pharmacological treatment avenue. Given that new targeted therapies are on the rise, we identified that PSMA inhibition
improved the effect of PI3K and mTOR inhibitors in vitro
(Fig. 5, A–D; and Fig. S4, A and B). Because the PSMA inhibitor 2-PMPA has been previously used in clinical studies
as a neuroprotective agent for diseases like multiple sclerosis
(Zhou et al., 2005; Rahn et al., 2012b), we used it to prime
animals that had PSMA-expressing xenografts and observed
reduced tumor volume and growth (Fig. 6, A–C; and Fig. S5,
A–I). Importantly, dose escalation further decreased tumor
growth in animals with PSMA-positive xenografts (Fig.
S5 J), and ablation of PSMA expression impaired tumor
growth (Fig. S5, K–M).
Because PSMA activates the PI3K pathway and the AR
negatively regulates PI3K, we next asked whether concomitant inhibition of the AR pathway and PSMA-mediated activation of PI3K could improve treatment of PSMA-expressing
tumors. We found that animals treated with either the anti
androgen enzalutamide or 2-PMPA had smaller tumors
165
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total calcium content than cells lacking this enzyme (Fig. S3
G), this indicates that prostate cancer may rapidly mobilize
calcium from the endoplasmic reticulum to the cytoplasm for
signal transduction. Inhibition of PSMA’s enzymatic activity
decreased the levels of inositol trisphosphate (Fig. S3 H),
demonstrating that PSMA may have first stimulated mGluR
I at the plasma membrane via glutamate, which in turn triggered phospholipase C to generate inositol trisphosphate that
activated endoplasmic reticulum’s inositol trisphosphate receptors to release calcium to the cytosol. Indeed, activation
of mGluR I and initiation of downstream cytoplasmic calcium efflux is mediated by PSMA at the plasma membrane,
where PSMA colocalized tightly with the two members that
constitute the mGluR I family (mGluR1 and mGluR5; Fig.
S3 I). Hence, in order to relay environmental and nutrient
cues to intracellular oncogenic signals using calcium as secondary messenger, PSMA at the plasma membrane has to
be enzymatically active, as expression of enzymatically inactive PSMA (Ghosh and Heston, 2003) abolished calcium
mobilization in the presence of glutamated folate, whereas
mGluR I was still functional (Fig. 4 C and Fig. S3 J). Overall, these data show that PSMA uses glutamated folate as its
substrate for the production of glutamate that will locally
activate mGluR I, leading to downstream signaling that supports prostate cancer progression.

than control animals (Fig. 6 D). However, marked regression
was observed in animals that received the antiandrogen and
PSMA inhibitor, where the volume of 9 out of 10 tumors
decreased (0 out of 10 tumors regressed with enzalutamide
alone, and 4 out of 10 tumors treated with 2-PMPA decreased;
Fig. 6 D and Fig. S5 N, inset). Combination therapy with
enzalutamide and an mGluR I antagonist indeed conferred
a therapeutic benefit, although it was less effective because
of the poor aqueous solubility and stability of the mGluR I
antagonist (Fig. S5 N). We further confirmed that treatment
with 2-PMPA did not affect the growth of xenografts lacking
PSMA that were implanted in PSMA+/+ or PSMA−/− animals
(Fig. S5, O and P), indicating that the inhibitor’s therapeutic
effect is associated with inhibition of the enzymatic activity
166

of tumor-expressed PSMA. Overall, these data further suggest that inhibition of PSMA in vivo may confer a therapeutic benefit, where by targeting the tumor’s PSMA, its PI3K
signaling is suppressed and off-tumor–associated toxicities
caused by PI3K signaling inhibition are averted.
PSMA expression in prostate cancer patients
correlates with Akt activity
After showing that PSMA inhibition provides a therapy benefit and that PSMA activates p110β-dependent Akt signaling,
and because prior work has identified PSMA as a promising
biomarker for prostate cancer, we investigated whether PSMA
expression was associated with distinct molecular profiles in
patients, allowing stratification toward personalized, precision
PSMA activates PI3K–Akt signaling via mGluR I | Kaittanis et al.
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Figure 6. Inhibition of PSMA’s enzymatic activity in vivo provides a treatment benefit. (A and B) Male, athymic nude mice with LNCaP-Ctrl xeno
grafts on both of their flanks were treated daily with vehicle (1× PBS) or PSMA inhibitor (2-PMPA) administered i.v. immediately after implantation of
the cells (n = 10 mice per cohort). Graphs show mean ± SEM. ****, P < 0.0001 (unpaired t test). Inset shows the day where the tumors were first detected
(n = 10 mice per cohort). (C) Survival curves of mice bearing LNCaP-Ctrl xenografts on their flanks (n = 10 animals per cohort). The animals received daily
i.v. treatment (vehicle: 1× PBS; PSMA inhibitor: 2-PMPA) during the course of the study (75 d after implantation; day 0, implantation day). p-value was
determined using the Gehan–Breslow–Wilcoxon test. (D) Waterfall plot of animals having bilateral LNCaP-Ctrl xenografts on their flanks (n = 5 mice per
group). Treatment was administered daily i.v. on day 24 after xenograft implantation (enzalutamide, 0.5 mg/kg; 2-PMPA, 20 mg/kg; Enz + 2-P, 0.5 mg/kg
enzalutamide and 20 mg/kg 2-PMPA). The black arrowhead on the timelines of C and D indicates the day of xenograft implantation, the purple arrowhead
the day treatment started, the purple line the length of treatment, and the continuous blue line that the treatment was daily.

Discussion
Patient stratification has long been sought for treatment optimization of men with primary and metastatic prostate cancer.
The carboxypeptidase PSMA, which is strongly expressed on
prostate cancer, has been used increasingly as target to guide
therapy and imaging agents to prostate cancer, yet its biological role in the disease remained elusive and unexplored.
Using transcriptomics, proteomics, and imaging, we show for
the first time that PSMA provides a signaling function by releasing glutamate from folic acid (vitamin B9). The glutamate
activates nearby metabotropic glutamate receptors. These
GCPRs lead to activation of p110β and concomitantly negatively regulate the AR pathway. Critical to signaling initiation
is PSMA’s processing of glutamated substrates, which activate proximal mGluR I, reminiscent of the enzyme’s function
within the synaptic clefts of the central nervous system. This
indicates also that the vitamin B9 (folic acid) is a potential
accelerator of prostate cancer, because it provides glutamate
through PSMA. Importantly, a recent large study of almost
15,000 men showed that individuals with higher blood folate
levels were at greater risk of high-grade prostate cancer (Price
et al., 2016), underscoring the importance of our work.
Previous studies have shown that Akt signaling in prostate cancer is driven by the p110β isoform of PI3K by an
JEM Vol. 215, No. 1

unidentified GPCR (Jia et al., 2008). In line with this, it was
demonstrated that inhibition of p110β confers a therapeutic
advantage in vivo and that combination therapy with PI3K
and AR inhibitors suppresses the reciprocal negative feedback
loop between these two pivotal signaling axes in prostate cancer (Carver et al., 2011). However, to our knowledge, there
have been no efforts to identify the mechanism by which
a GPCR specifically activates p110β in animal models and
prostate cancer patients. Prior work has shown that PSMA is
overexpressed in prostatic neoplasias and that AR inhibition
up-regulates PSMA levels (Evans et al., 2011). Additionally,
PSMA was identified as a zinc metalloproteinase capable of
processing glutamated folates, with the released folate providing a proliferative advantage to prostate cancer cells (Yao
and Bacich, 2006; Klusák et al., 2009). Before these studies,
the field of neuroscience provided evidence that the enzyme’s
role in the central nervous system is to modulate excitatory
signaling through the processing of NAAG with refined spatiotemporal regulation. Different groups implied that the
spatial regulation of PSMA at the plasma membrane might
facilitate oncogenic signaling in prostate cancer, although the
mechanism remained elusive (Rajasekaran et al., 2005; Colombatti et al., 2009). Our findings bridge this significant gap
in knowledge and experimentally show that PSMA colocalizes with mGluR I members on the plasma membrane of
prostate cancer cells, providing a mechanistic link between
PSMA and mGluR I as the participating GPCR that activates
p110β signaling. The causality between PSMA enzymatic activity and p110β-driven Akt signaling shown by our work
provides an appealing justification for the β-isoform–specific
induction of PI3K signaling in prostate cancer, irrespective
of PTEN status, and establishes a central functional role of
PSMA as a diagnostic and therapeutic target for the inhibition
of GPCR-driven oncogenesis in cancer. Collectively, our data
support the hypothesis that PSMA converts environmental
signals, such as nutrient abundance, into proliferative signals
that drive pro-oncogenic activities during prostate cancer.
Our findings have important clinical implications for
prostate cancer patient treatment. Expression of PSMA correlates with activation of the PI3K–Akt pathway in patients.
Noninvasive PET imaging can interrogate PSMA in the tumor
with agents that are already in advanced clinical trials in the
United States and Europe. Considering that the levels of PSA
are not an accurate predictor of disease status and that prostate
cancer is not FDG avid, our work suggests that PSMA-based
PET imaging not only demonstrates the presence of prostate
cancer but also noninvasively diagnoses a patient’s underlying
molecular signaling aberrations, providing improved patient
stratification and better treatment. Because PSMA is expressed
in the neovasculature of other solid tumors and many of these
tumors coexpress members of the mGluR family (Ristau et
al., 2014; Yu et al., 2017), our data argue that PSMA might
additionally have similar function in the tumor neovasculature.
Lastly, the observation that PSMA activates the PI3K
pathways and negatively regulates the AR pathway has sig167
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medicine. Therefore, we screened a tissue microarray consisting of samples from 76 prostate cancer patients and found that
expression of PSMA correlates with phosphorylation of the
Akt target 4EBP1 (Fig. 7 A and Fig. S4, C–H). PTEN’s levels
did not correlate with PSMA levels and 4EBP1 status (Fig. S4
F). These findings prompted us to examine whether noninvasive assessment of PSMA expression through PET imaging
could predict Akt activation in patients and thus serve as a
potential prognostic marker that guides therapy.We examined
whether Akt phosphorylation is higher in patients with elevated PSMA levels, determined noninvasively with PET and
magnetic resonance imaging (MRI) and the PSMA-specific
probe 68Ga-HBED-CC before prostatectomy (Eder et al.,
2012; Maurer et al., 2016). After prostatectomy, sections of the
removed tumor underwent histopathological analysis, including quantitative immunofluorescence microscopy for PSMA
and phosphorylated Akt, in order to obtain global tumor molecular information and address disease heterogeneity issues
(Fig. 7, B and C). Principal component analysis (PCA) identified that PSMA expression and tracer uptake more strongly
correlated with Akt’s phosphorylation at S473 than other
clinical indicators of prostate cancer, such as Gleason score
and PSA (Fig. 7, D and E). Despite the variability among
samples from each patient (which is common because of cancer’s heterogeneity), these findings show that PSMA-based
PET imaging can serve as a predictor of the global activation
status of the PI3K–Akt pathway in a prostatic lesion. Particularly when grading nearly identical tumors, this will provide a
new means of risk stratification for patients and help identify
those patients that require more aggressive therapy.
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that mGluR I is expressed in several cancers, including melanoma, lung, and pancreatic, and PSMA is expressed on the
neovasculature of solid tumors. It is also possible that PSMA
may up-regulate AKT activity via the calcium-dependent activation of mTORC2, which in turn can phosphorylate AKT
(Huang et al., 2013; Josselyn and Frankland, 2013).This might
suggest the presence of a positive feedback loop, which can
be part of future investigational efforts. In conclusion, because
several PSMA-specific imaging agents are entering the clinic
and one in seven men will be diagnosed with prostate cancer,
our findings may facilitate biology-based treatment planning
toward precision oncology.
Materials and methods
Materials
Monoglutamate folate was purchased from Sigma-Aldrich,
whereas the tri- and pentaglutamate folates were obtained
from Schircks Laboratories. The following chemicals were
acquired from Tocris: 2-PMPA (PSMA inhibitor), (S)-3,5,DHPG (mGluR I agonist), l-quisqualic acid (mGluR I agonist), L-AP3 (mGluR I antagonist), U73122 (phospholipase
C inhibitor), IEM 1460 (AMPAR blocker), D-AP5 (NMDA
receptor antagonist), and NPS 2390 (mGluR I antagonist).
From Sigma-Aldrich, we also obtained N-acetyl-L-cysteine
and dimethyl sulfoxide. We purchased the following compounds from Selleck Chemicals: BKM120 (pan-PI3K inhibitor), BYL719 (PI3K-p110α inhibitor), GSK2636771
(PI3K-p110β inhibitor), enzalutamide (AR antagonist),
everolimus (mTOR inhibitor of FKBP12), AZD8055
(ATP-competitive mTOR inhibitor), INK128 (mTORC1/2
inhibitor), and XL184 (VEGFR2 inhibitor). All chemicals
were stored and their solutions prepared according to the
suppliers’ recommendations.
Cell lines
The human prostate cancer cell lines LNCaP, 22Rv1, and
PC3, as well as the murine Lewis lung carcinoma cell line

Figure 7. Expression of PSMA in patients allows their stratification in distinct groups that reflect activation of the Akt/mTOR pathway.
(A) Clustering analysis of patient tissue microarray data formed three distinct clusters where elevated PSMA expression correlated with enhanced 4EBP1
phosphorylation in cluster B, whereas decreased PSMA expression was associated with decreased 4EBP1 phosphorylation in cluster C. Cluster A underlines
disease and sample heterogeneity, where mixed PSMA staining (sample with PSMA-positive and negative foci) was associated with either lack or low phosphorylation of 4EBP1. The expression of PTEN is displayed but was not considered in the clustering analysis. (B and C) PET/MRI of prostate cancer patients
using the PSMA-specific probe 68Ga-HBED-CC, and immunofluorescence microscopy analysis of cancer tissue from patients obtained after prostatectomy.
Twelve patients were imaged with PET/MRI, and tissue samples from multiple sites of the biopsy were screened. Representative images are shown, with the
corresponding microscopy slides stained for PSMA, pAKTS473 (Cell Signaling), and Hoechst 33342 (bars, 50 µm). (D and E) Biplot representation suggests that
PSMA expression is associated with Akt phosphorylation at residues S473 and T308 and that PSMA immunostaining and PSMA-based PET (SUV values) are
both good indicators of Akt’s phosphorylation, as these parameters are closer to Akt in the two-dimensional space defined by the primary principal components PC1 and PC2 than other clinical parameters. The open circles show the samples stained per patient and underlie sample variability caused by the
heterogeneous nature of the disease. Biplots derived from PCA of patients imaged with PET/MR and their samples underwent histopathological analyses,
including immunofluorescence microscopy for phosphorylation of Akt on residues S473 and T308. Gleason, Gleason score; SUVmean, mean standardized
uptake value of PSMA tracer. (F) Schematic representation of the overall pathway involving PSMA and induction of tumor-supporting signaling based on
our data. Free glutamate released from PSMA after processing of glutamate-containing substrates activates mGluR I receptors found on the plasma membrane of prostate cancer cells. Activation of the glutamatergic system induces downstream calcium signaling and activation of the PI3K cascade, positively
regulating tumor growth.
JEM Vol. 215, No. 1
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nificant clinical implications, because PSMA and mGluR I
inhibitors could be used in tandem with antiandrogens, such
as enzalutamide or abiraterone. Our work with preclinical
inhibitors of mGluR I, such as NPS 2390, and the PSMA
inhibitor 2-PMPA, which has been previously tested in the
clinic, establish this combination therapy strategy in vitro and
in vivo. Because prior work showed that the combination of
inhibitors of the AR and PI3K is required to elicit therapeutic
efficacy in prostate cancer (Carver et al., 2011), and that PI3K,
Akt, or mTOR inhibitors have some limitations, including
off-target effects caused by their constitutive expression in
other organs, inhibition of PSMA can be an alternative therapeutic venue. In addition to pharmacological treatment, the
results of the present study may provide dietary guidelines for
cancer patients, such as folate-fortified food like bread and
pasta (or frequently as an additive in Chinese food in the
United States), and multivitamin supplements might support
the pro-cancer activity of PSMA. It may also be intriguing
if future studies delineate the temporal dynamics among
PSMA-facilitated calcium mobilization, PI3K–Akt activation, and AR inhibition, along with evaluation of the status
of PKC isozymes that are regulated by the AR in prostate
cancer (Tanaka et al., 2003; Gonzalez-Guerrico et al., 2005;
Xiao et al., 2009; Shankar et al., 2016) and control the activity
of protein phosphatase 2, which modulates Akt.
In summary, our results demonstrate that apart from
being a biomarker of prostate cancer, PSMA carries a previously unknown critical functional role in disease progression,
transmitting environmental cues stemming from nutrients to
initiate an intricate intracellular signaling repertoire. Specifically, through release of glutamate from glutamated folates,
including vitamin B9, it activates the glutamatergic system,
mobilizing calcium, activating PI3K (Fig. 7 F), and triggering a growth-prevailing cascade into the cell. As we have
demonstrated, this provides new insights on disease dynamics, including the reason for the prevailing p110β signaling
in prostate cancer, and therapeutic approaches, considering

Bioinformatics analyses
The GeneChip Human Genome U133A 2.0 array from
Affymetrix, Inc. was used to determine gene expression levels in cells expressing or lacking PSMA. Each cell line was
analyzed in triplicate, after growth of cells to confluence on
Petri dishes, supplemented with complete media. Before total
RNA extraction with TRIzol, the cells were washed three
times with warm 1× PBS. The preparation of the arrays’ samples and subsequent data analysis were done at MSKCC’s
Integrative Genomics Operation and Bioinformatics Core.
To categorize the most differentially affected genes, we determined each gene’s function through the NCBI Gene data
base. The microarray data of the screened PSMA-positive
and PSMA-negative human prostate cancer cells have been
deposited to the National Center for Biotechnology Information’s Gene Expression Omnibus repository (accession no.
GSE104419). For the bioinformatics analyses of data from
prostate cancer patients, we used a dataset recently reported
170

(Hieronymus et al., 2014). In brief, from this dataset’s initial
cohort (n = 168, PMID 25024180), we used the localized
cases of primary tumors that have not had any neoadjuvant
treatment and matched normal samples of patients that underwent prostatectomy at MSKCC, following institutional
review board approval. For gene set enrichment analyses, we
used the corresponding gene sets that met the p-value < 0.01,
false discovery rate q < 0.2 significance thresholds across the
examined cohorts and cell lines. Gene networks were determined and visualized through Cytoscape, based on the intersection of enriched gene sets that meet the significance
thresholds in the studied cohorts/cells. PSMA expression was
binned as high z >2 expression versus not, and PSMA expression was identified as a prognostic for biochemical recurrence
and metastasis even after correcting for the clinical Stephanson nomogram score, which combines other prognostic variables like Gleason score and margins, through multivariate
Cox regression. PSMA’s association with outcome was examined through a multivariate regression model, which effectively corrects for the nomogram score, which collected all
of the clinical and pathological variables, including Gleason
grade, into one prognostic variable.
Epifluorescence microscopy for mGluR I and calcium studies
in prostate cancer cells
For microscopy studies, the cells were grown on poly(lysine)coated chamber glass slides at a density of 40,000 cells per
chamber. The cells were stained with anti–human PSMA
antibody (Dako) and the rabbit polyclonal anti–human
mGluR1/5 antibody (Novus Biologicals). Secondary fluorophore-conjugated antibodies were obtained from Abcam,
and the nuclear stain Hoechst 33342 was purchased from Invitrogen. The slides were first examined on a Nikon Eclipse
Ti-E fluorescence microscope, followed by imaging on the
MSKCC’s Molecular Cytology Core Leica SP5 laser-scanning confocal microscope (Leica Microsystems, Inc.). To
quantify calcium levels, we used the high-throughput Fluo-4
Direct assay from Invitrogen and the SpectraMax M5 plate
reader from Molecular Devices. For these studies, cells were
seeded at a density of 20,000 cells per well on poly(lysine)treated black, clear-bottom, 96-well plates (Corning, Inc.),
followed by overnight growth. Each well’s total volume was
set at 100 µl, with cells receiving 10 µl of control (1× PBS)
or treatment solution, after dilution of the stock solutions of
the various compounds with 1× PBS. Addition of the Fluo-4
reagent, instrument set, and acquisition parameters were performed in accordance to the assay’s user handbook, which
was provided by the manufacturer.
Identification of PSMA’s effect on the
activation of signaling pathways
To determine whether PSMA affects the phosphorylation
of key kinases, we used the human phosphokinase antibody
array from R&D Systems, Inc. (ARY003B) and the PathScan
Akt signaling antibody array kit (9700; Cell Signaling, Inc.).
PSMA activates PI3K–Akt signaling via mGluR I | Kaittanis et al.
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LL2, were obtained from the American Type Culture Collection. All cell lines were regularly tested for mycoplasma
contamination and authenticated by DDC Medical through
the STR profiling method. The stocks of the human prostate cancer cells lines were grown in a humidified incubator
at 37°C, 5% CO2 and supplemented with RPMI 1640 medium (Gibco) that contained 10% fetal bovine serum (Gemini Bio-products), glutamine ([Gln]fn = 3 mM), 1% Hepes
buffer, and 1% penicillin/streptomycin. LL2 cells were grown
in DMEM (Gibco) that contained 10% fetal bovine serum
and 1% penicillin/streptomycin. To generate cells that lacked
PSMA, we used LNCaP cells, which express PSMA, and the
Platinum Select retroviral shRNA-mir platform (DU53991)
from TransOMIC Technologies, Inc. to knock down the gene
PSMA that encodes PSMA (gene ID 2346), following the
supplier’s guidelines. Selection was done in the presence of
puromycin, and confirmation of generation of cells lacking
PSMA was achieved with immunoblot analysis, using an
MA-1; Abcam). Quananti–human PSMA antibody (YPS
titative real-time PCR was performed by Memorial Sloan
Kettering Cancer Center’s Integrative Genomics Operation
using total RNA extracted with TRIzol (Invitrogen) from
cells grown to confluence on Petri dishes, followed by reverse
transcription to cDNA using the ProtoScript First Strand
cDNA synthesis kit (New England Biolabs), qPCR with the
CFX real-time PCR detection system (Bio-Rad), and primer
sequences previously reported (Yates et al., 2012). Normalization for PSMA expression was done with LNCaP-Ctrl
PSMA expression serving as the calibrator for all samples, and
expression of β actin served as an endogenous control. The
enzymatically inactive PSMA mutant was generated according to a prior study (Ghosh and Heston, 2003), and the ability
of PSMA-expressing cells to process monoglutamated folate, releasing free glutamate in the solution, was determined
through Molecular Probes’ Amplex Red Glutamic Acid assay
following the supplier’s protocol (Thermo Fisher Scientific).
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glutamate folate ([Glu-fol]fn = 20 µM) and inhibitors ([inhibitor]fn = 200 nM) for 2 h at 37°C, 5% CO2, followed by
fluorescence emission measurements using the Odyssey platform (LI-COR Biosciences).
Determination of nitric oxidase synthase activity, and
quantification of PSA in vitro
The activity of nitric oxidase synthase, which is a downstream
target of Akt, was evaluated with the nitric oxide synthase
activity kit (Cayman Chemical), following isolation of the
cells’ extracellular medium. For this, cells were seeded on
poly(lysine)-coated Petri dishes at a density of 1,000,000
cells and grown in the presence of complete medium for at
37°C, 5% CO2 for 48 h. This was followed by aspiration of
the media, washing with 1× PBS, and addition of serum-free
medium and 2-PMPA. The cells were incubated at 37°C, 5%
CO2, and media were collected at the designated time points,
followed by sample processing and analysis in line with the
assay-provided protocol. Similarly, the levels of the PSA were
determined in the human prostate cancer cell line LNCaP,
which expresses the AR and has a functional AR cascade.
The cells were cultivated as mentioned above in this section
and treated with 2-PMPA for the time indicated in the corresponding figures, followed by media isolation and analysis
with the DELFIA Prostatus assay (PerkinElmer).
In vitro and in vivo chemotherapy experiments
Cells were seeded at a density of 20,000 cells per well on
poly(lysine)-coated black, clear-bottom, 96-well plates after
growth for 24 h in the presence of complete medium at 37°C,
5% CO2. The medium was then removed, and fresh complete
medium was added, which was supplemented with the listed
inhibitors. Control wells were treated with 1× PBS or 1×
PBS that had equimolar DMSO concentration to correspond
to the DMSO concentration of inhibitors whose stock solutions were in DMSO and diluted to the desired compound
concentration with 1× PBS. Viability was determined with
the Alamar blue assay (Thermo Fisher), after aspirating the
treatment medium and addition of 10% Alamar blue–containing fresh medium, and incubation for 3 h at 37°C, 5%
CO2. Inhibition of PSMA with 2-PMPA in LNCaP-Ctrl
cells had comparable results with a previous report that used
LNCaP cells (Yao and Bacich, 2006). Animal studies were
conducted with adult, male, athymic, nude mice obtained
from Harlan Laboratories. All animal studies were conducted
in accordance to MSKCC’s Institutional Animal Care and
Use Committee, with procedures approved by MSK
CC’s
Research Animal Resource Center. For the experiment with
animals bearing LL2-derived tumors, adult male PSMA−/−
C57BL/6J mice were obtained from MSK
CC’s internal
small-animal colony. Xenograft engraftment was achieved by
subcutaneous injection of 1,000,000 cells in 100 µl Matrigel on each flank, unless otherwise stated. All compounds
were administered i.v. (100 µl), with control cohorts treated
with vehicle (1× PBS or 1× PBS with equimolar DMSO
171
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The cells were seeded on poly(lysine)-coated Petri dishes at a
density of 1,000,000 cells per dish, followed by 24-h growth
at 37°C, 5% CO2 in complete medium and a 24-h starvation in basal medium. Before the addition of 100 µl control
(1× PBS) or experimental treatment, cells were supplemented with fresh media, as mentioned in the figure legends.
For compounds whose stock solutions were in DMSO and
subsequently diluted in 1× PBS, the corresponding control
cell cohort was treated with 1× PBS that contained equimolar concentration of DMSO, with each cohort consisting
of three replicates. After incubation with the compounds of
interest, the cells were washed three times with chilled 1×
PBS, followed by lysis with RIPA buffer (Sigma-Aldrich).
The cell lysates were processed according to the recommendations of the arrays’ suppliers, and protein concentration was
determined using the bicinchoninic acid assay (Pierce Biotechnology). After following the setup and processing steps
described in each array’s user manual, the arrays were scanned
and signal was quantified using the near-infrared fluorescence
Odyssey imaging platform (LI-COR Biosciences, Inc.).
Changes in phosphorylation were calculated with respect to
the corresponding untreated control cells, which were cells of
the same background. Evaluation of a protein’s global phosphorylation status was determined via changes in its isoelectric point using the NanoPro 1000 system (Protein Simple)
and primary rabbit anti–human monoclonal antibodies from
Cell Signaling. The cells were prepared and treated similarly
to the phosphorylation array studies, followed by lysis with
the Bicine/CHAPS buffer (Protein Simple). All reagents and
supplies, including sample diluent, ampholyte, standards, and
microcapillaries, were purchased from Protein Simple, with
the samples prepared according to the guidelines of the instrument’s manufacturer, having a protein concentration of 1
µg/µl and same DMSO content as the ampholyte. Detection
was achieved through a biotin-conjugated goat anti–rabbit
secondary antibody and streptavidin-conjugated horseradish
peroxidase using Compass 2.7.1 software for Windows XP to
control the instrument and data acquisition and analysis (all
from Protein Simple). Human inositol 1,4,5-trisphosphate
levels were quantified with the corresponding Cusabio ELI
SA kit (Cosmo Bio) according to the supplier’s guidelines,
using cells grown on Petri dishes followed by cell lysis. The
SpectraMax M5 microplate reader was used, recording absorbance at 450 nm with the correction wavelength set at
600–630 nm.The activation of Akt by PSMA was determined
with the fluorescent substrate of Akt LS456, which exhibits
increased fluorescence emission at 700 nm upon phosphorylation by Akt (Shen et al., 2013). LNCaP-Ctrl cells were
seeded at 10,000 cells per well on poly(lysine)-coated black,
clear-bottom 96-well plates, and after overnight growth in
complete media they were administered LS456 ([LS456]fn =
5 µM), as previously reported. After 24 h at 37°C, 5% CO2,
the cells were washed three times with warm 1× PBS, supplemented with 100 µl basal medium that was free of serum,
glutamate and folate for 24 h, and then treated with mono-

Siemens Healthcare), with mpMR-examination that included T2w, DWI, and DCE of the prostate being performed
simultaneously during a 15-min PET scan. A workflow chart
of this protocol and details for PET-data reconstruction, including the use of the T1w VIBE Dixon for attenuation correction, have been published previously (Souvatzoglou et al.,
2013). All reported investigations were conducted in accordance with the Declaration of Helsinki as well as national
regulations. Consent to publish photos was obtained from
all patients. The retrospective data analysis was approved by
the ethics committee of the Technical University of Munich,
Germany (permit 5665/13).

Immunohistochemical examination of xenografts and
prostate cancer patient–derived tissue microarray
Human prostate cancer xenografts that were established in
adult, male, athymic, nude mice were collected after the animals were euthanized, followed by the excised tumors fixation in 10% neutral-buffered formalin for 48 h. They were
then grossed and embedded in paraffin, followed by sectioning to 4 µm onto charged glass slides in the MSKCC Molecular Cytology Core. Immunohistochemical staining and
processing was done at HistoWiz, Inc. using human anti–
PSMA antibody from Dako and human anti–pAkt1 and panAkt antibodies from Cell Signaling. The slides were imaged
using the Zeiss MIRAX MIDI slide scanner and Pannoramic
Viewer software (3DHistech Ltd.), whereas quantification of
immunohistochemistry signal intensity was done with ImageJ
after normalization to object count. The tumor tissue micro
array was generated from localized prostate cancer specimens
obtained from the MSKCC Urology Service, and informed
consent was obtained from all subjects. Approval was obtained
from the institutional review board and the Human Tissue
Utilization Committee before study of human specimens.
Immunostaining was done with the human anti–PSMA
antibody from Dako and human anti–phospho-4EBP1 and
anti–PTEN antibodies from Cell Signaling at the MSK
CC Pathology Department.

Epifluorescence microscopy of histology slides of biopsies
from prostate cancer patients imaged with PET/MRI
For further analysis and to obtain additional molecular information, representative tissue sections containing localized
prostate cancer were prepared from each radical prostatectomy of the patients undergoing PET/MRI at the Technical
University of Munich, Germany. Samples were fixed in 10%
neutral-buffered formalin for 48 h, grossed, and embedded in
paraffin before sectioning to 4 µm onto charged glass slides.
The slides were deparaffinized as follows: twice in xylene for
5 min each, followed by twice in 100% ethanol for 5 min
each, followed by twice in 95% ethanol in water for 5 min
each and briefly in pure water. Two slides each from nearly
all cases were then immediately probed with a solution containing 10% FBS (Gibco) in anti–PSMA antibody (1× 3E6,
M3620; Dako) and either anti-pAKT(S473) (4060S, 1:83;
Cell Signaling Technologies) or anti-pAKT(T308) (D25E6,
1:83, Cell Signaling Technologies) antibody for 1 h at room
temperature. The slides were then washed twice for 5 min
each with 1× PBS and then probed with goat anti-mouse
secondary antibody-fluorescein conjugate (ab97022, 1:250;
Abcam) with chicken anti–rabbit secondary antibody conjugated to Alexa Fluor 647 (A21443, 1:250; Invitrogen) in 1×
PBS for 30 min at room temperature. After aspiration of the
secondary antibody solution, the slides were then exposed to
Hoechst 33342 dye for 1.5 min (H3570, 1:1,000 in 1× PBS;
Invitrogen). The slides were then washed twice more with
1× PBS for 5 min each before adding mounting medium
(Dako Faramount Aqueous Mounting Medium) and a glass
coverslip. The slides were then immediately viewed using
a Nikon 80i upright epifluorescence microscope equipped
with a Nikon DS-Qi1Mc dark-field CCD camera and excited by a Nikon Intensilight C-HGFI lamp. All images were
recorded and processed using Nikon Imaging Software Elements, which was also used for signal quantitation.

PET/MRI acquisition
Images were obtained after intravenous injection of 68GaHBED-CC constituting an extracellular PSMA ligand
synthesized as described previously (Martin et al., 2014). Simultaneous PET/MRI was performed using an integrated
whole-body PET/MRI system (Siemens Biograph mMR;

Statistics
All data are presented as mean ± SEM unless otherwise
stated. P-values were derived from two-tailed Student’s t
tests using the Shapiro–Wilk tests for normally distributed data, the Mann–Whitney U tests for nonnormally
distributed data, or ANO
VA (GraphPad Prism; Graph-
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concentration for compounds whose stocks were in DMSO
and then diluted to the desired concentration with 1× PBS;
DMSO content was less than 2%).Tumor measurements were
taken with calipers, and the animals were anesthetized with
isoflurane whenever needed. They were euthanized once the
tumor reached a diameter of 10 mm, in accordance with institutional policies (maximum tumor volume allowed by Institutional Animal Care and Use Committee was 524 mm3).
Control animals with LNCaP-Ctrl xenografts had established
tumors ∼3 wk after xenograft implantation, and the tumors
reached the maximum allowable volume within 3 to 4 wk.
Drug dosages were based on the compounds’ characteristics and to prevent any side effects. For instance, 2-PMPA,
which is very hydrophilic and rapidly cleared from the body,
was administered at higher concentration than enzalutamide,
which is hydrophobic, has 98% protein binding, and has a
biological half-life of 9 d. To examine whether PSMA plays
a role in early tumor establishment and development, animals were treated with 2-PMPA immediately after xenograft
implantation. Imaging studies were conducted at MSKCC’s
Small Animal Imaging Core facilities using the IVIS Spectrum system (PerkinElmer).

Online supplemental material
Fig. S1 shows that PSMA expression is up-regulated in cancer.
Fig. S2 shows that enzymatically active PSMA is required to
activate p110b-dependent downstream signaling. Fig. S3 shows
that PSMA processes glutamated folates in prostate cancer
and that the released glutamate activates mGluR I. Fig. S4
shows that PSMA activates the PI3K–Akt axis in vitro and
in prostate cancer patients. Fig. S5 shows in vivo evaluation
of the inhibition of PSMA as a potential therapy in prostate
cancer. Table S1 shows expression of PSMA associates with
biochemical recurrence in prostate cancer patients. Table
S2 shows expression of PSMA associates with metastasis in
prostate cancer patients.
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Figure S1. PSMA expression is up-regulated in cancer. (A) Immunoblot of the human prostate cancer cell lines used in the present work (rhPSMA,
recombinant human PSMA). (B) Quantitative real-time PCR to assess expression of PSMA. LNCaP-Ctrl cells were treated with the PSMA inhibitor 2-PMPA for
48 h (n = 3 per group). Graph shows mean ± SEM. ns, not significant; ***, P < 0.001; ****, P < 0.0001 (ordinary one-way ANOVA). Table lists the graph’s data of
relative PSMA expression, where LNCaP-Ctrl PSMA expression served as the calibrator for all samples. (C) Immunoblot analysis for prostate cancer cells expressing or lacking PSMA (PSMAmut, express an enzymatically inactive form of PSMA; PC3-PSMAwt_H, express high levels of wild-type PSMA; PC3-PSMAwt_L,
express low levels of wild-type PSMA). (D–G) Quantification of immunohistochemistry images from mouse xenografts. Signal intensity analysis of slides
from PC3-Ctrl and PC3-PSMA tumors grown in athymic nude mice and stained with the corresponding human antibodies. Intensity was measured using
the ImageJ software (nPC3-Ctrl_anti-PSMA = nPC3-Ctrl_anti-pan-AKT = 10; nPC3-Ctrl_anti-pAKT1 = nPC3-PSMA_anti-PSMA = nPC3-PSMA_anti-pan-AKT = nPC3-PSMA_anti-pAKT1 = 15). (G) Ratio of
phospho-AKT1 intensity (IpAKT1) over the mean of the total AKT staining intensity (IpanAKT) for each group’s slides. Graphs show mean ± SD. ns, not significant;
***, P < 0.001; ****, P < 0.0001 (unpaired t test).
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Figure S2. Enzymatically active PSMA is required to activate p110b-dependent downstream signaling. (A) Inhibition of PI3K’s catalytic subunits
differentially affects Akt’s phosphorylation. LNCaP-Ctrl cells were grown in complete medium and treated for 2 h with the corresponding inhibitor. Control
cells were treated with 1× PBS. Changes in Akt’s phosphorylation were determined with the NanoPro system (n = 3 per treatment). Graph shows mean ±
SEM. **, P < 0.01; ***, P < 0.001 (ordinary one-way ANOVA). (B) Addition of monoglutamate folate (Glu-Fol) did not affect Akt’s phosphorylation in LNCaP
cells lacking PSMA (LNCaP-KD). Cells were starved for 24 h and then supplemented with basal medium and different concentrations of Glu-Fol (+ =
15 µM; ++ = 30 µM), followed by NanoPro analysis (n = 3 per treatment). Graph shows mean ± SEM. (C–E) PC3-PSMA cells were starved for 24 h in basal
medium, followed by 2 h stimulation (mut, mutant PSMA unable to process glutamate folate; wt, enzymatically active wild-type PSMA). Phosphorylation
was determined with the NanoPro system. *, P < 0.05; ***, P < 0.001. (F–K) PSMA regulates Akt phosphorylation regardless of the presence of PTEN (22Rv1:
PTEN-positive; LNCaP: PTEN-deficient). The cells were starved for 24 h and then treated with Glu-Fol and the mTORC1/2 inhibitor (INK 128) for 2 h. Changes
in phosphorylation were determined with the NanoPro platform (n = 3 per treatment). Graphs show mean ± SEM. ns, not significant; *, P < 0.05; **, P < 0.01
(unpaired t test). (L) Nitric oxide levels were measured with the nitric oxide synthase activity assay, because this enzyme is activated by Akt. LNCaP-Ctrl cells
were treated with 2-PMPA for the time indicated (n = 8 per treatment). (M) PSMA, through activation of the PI3K–Akt signaling cascade, down-regulates the
androgen receptor pathway. The activity of the androgen receptor pathway, reflected in production of PSA, was determined in LNCaP-Ctrl cells cultivated
in complete medium and treated with 2-PMPA (n = 6 per treatment) using the DELFIA Prostatus assay. Graphs show mean ± SEM. ns, not significant; *, P <
0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 (ordinary one-way ANOVA).
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Figure S3. PSMA processes glutamated folates in prostate cancer, and the released glutamate activates mGluR I. (A) Increase in cytoplasmic
calcium levels in LNCaP-Ctrl cells in response to addition of monoglutamated folate (Glu-Fol; vehicle: 1× PBS). Before treatment with Glu-Fol, the cells were
incubated in basal-RPMI medium that was free of serum, folate, and glutamate for 4 h at 37°C, 5% CO2. Detection was achieved with the Fluo-4 Direct
calcium kit. (B and C) Mono- and polyglutamate folates affect calcium levels in PSMA-expressing LNCaP-Ctrl prostate cancer cells grown in complete (B)
and basal (free of serum, glutamate and folate) medium (C; n = 8; Glu-Fol, monoglutamate folate; Glu3-Fol, triglutamate folate; Glu5-Fol, pentaglutamate
folate). (D and E) Changes in cytoplasmic calcium levels of LNCaP-Ctrl cells in the presence of monoglutamated folate, 2-PMPA (PSMA inhibitor), and an
agonist (l-quisqualic acid) or antagonist (L-AP3) of the glutamatergic system in complete medium (n = 8 per condition). The inset in D shows a representative wide-view immunofluorescence microscopy image of fixed LnCaP-Ctrl cells stained with the monoclonal mouse anti–human PSMA antibody, polyclonal
rabbit anti–human mGluR1/5 antibody, and Hoechst 33342. (F) Activation of mGluR I by its agonist (S)-3,5,-DHPG mobilizes calcium to the cytoplasm of
prostate cancer cells. (n = 8 per condition). The cells were in complete medium, and differences were calculated based on calcium levels of the corresponding untreated cells. (G) Quantification of cytoplasmic calcium levels in cells expressing (LNCaP-Ctrl and PC3-PSMA) or lacking PSMA and (LNCaP-KD and
PC3-Ctrl) in complete medium, through the Fluo-4 Direct assay. (H) Inositol trisphosphate (IP3) levels in prostate cancer cells grown in complete medium
and treated for 2 h with the PSMA inhibitor 2-PMPA. Changes in [IP3] were calculated with respect to the corresponding cell line grown in complete medium
without the inhibitor (n = 12 per condition). (I) Confocal laser scanning microscopy on fixed LNCaP-Ctrl cells stained with the antibodies listed above for
panel D's inset shows colocalization of mGluR1/5 and PSMA. Representative image of 20 scans is shown. Bar, 10 µm. (J) Evaluation of PSMA’s ability to process monoglutamate folate and release free glutamate, determined through the Amplex Red Glutamic Acid assay. Cells were deprived of serum, glutamate,
and folate for 4 h before treatment (PC3-PSMAwt: expressing wild-type PSMA; PC3-PSMAmut: expressing enzymatically inactive PSMA; n = 8 per condition).
Graphs show mean ± SEM. ns, not significant; *, P < 0.05, **, P < 0.01, ***, P < 0.001; ****, P < 0.0001 (ordinary one-way ANOVA).
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Figure S4. PSMA activates the PI3K–Akt axis in vitro and in prostate cancer patients. (A and B) Inhibition of PSMA improves response to chemotherapy. Suppression of PSMA’s enzymatic activity improves the cytotoxic activity of mTOR inhibitors (everolimus and AZD8055) and XL184 (VEGFR2 and
multikinase inhibitor). The cells were treated with these agents ([drug] = 200 nM) and 2-PMPA (200 nM) for 48 h at 37°C, 5% CO2 (n = 12 per treatment).
Graphs show mean ± SEM. *, P < 0.05, **, P < 0.01; ****, P < 0.0001 (ordinary one-way ANOVA). (C–F) Expression of PSMA is associated with phosphorylation
of the Akt target 4EBP1 in prostate cancer patients. Patient samples in a tissue microarray analyzed by PCA demonstrate that elevated phosphorylation of
the Akt-target 4EBP1 is associated with increased PSMA expression in prostate cancer with the majority of the data variance captured along the two primary principal components (PC1 and PC2). Scores of tissue microarray patient samples used for the PCA model of Fig. 7 A. The same data are plotted three
times color-coded for the expression of PSMA, 4EBP1, and PTEN, respectively. (G and H) Representative immunohistochemistry images of patient samples
corresponding to the clusters of Fig. 7 A.
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Figure S5. In vivo evaluation of the inhibition of PSMA as a potential therapy in prostate cancer. (A–I) The expression of PSMA can be assessed
with specific small-molecule probes. Near-infrared fluorescent images of PC3-Ctrl and PC3-PSMA xenografts with the fluorescent PSMA-targeting agent
YC-27 accumulating at the PSMA-expressing tumor (1 nM YC-27IV); images were acquired at 10 min, 1 h, 3 h, 5 h, and 24 h. After 24 h, the mouse was sacrificed, and tumors, muscle, liver, spleen, kidneys, and intestine were imaged. All images were acquired on a Pearl Impulse Imager (LI-COR Biosciences, Inc.).
(H and I) Expression of PSMA was also determined in vivo using the PSMA tracer [18F]DCFPyL and positron emission tomography (PET). A male NOD-SCID
mouse implanted with PC3-Ctrl and PC3-PSMA xenografts was administered 200 µCi (7.4 MBq) of [18F]DCFPyL i.v. in 200 µl of 1× PBS. Images were acquired with an eXplore VISTA small animal PET scanner (GE Healthcare) at 10 and 60 min. The dwell time at each bed position was 10 min for a total scan
time of 20 min. An energy window of 250–700 keV was used. Images were reconstructed using the FORE/2D-OSEM method (2 iterations, 16 subsets) and
included correction for radioactive decay, scanner dead time, and scattered radiation. (J–P) The expression of PSMA by the neoplastic lesion affects tumor
growth. (J) Survival plots of male, athymic nude mice with bilateral human prostate cancer xenografts on their flanks (n = 5 animals per cohort). The mice
with LNCaP-Ctrl tumors received daily i.v. treatment, upon tumor implantation (vehicle: 1× PBS; 2-PMPA [L]: 20 mg/kg; 2-PMPA [H]: 40 mg/kg). *, P < 0.05;
**, P < 0.01; ****, P < 0.0001 (log-rank [Mantel-Cox] test). (K–M) Mice with bilateral LNCaP-KD xenografts on their flanks developed small tumors, which grew
slowly and resulted in improved survival. The animals were treated with either vehicle (1× PBS) or 40 mg/kg 2-PMPA administered i.v. daily upon xenograft
implantation (nVehicle = n2-PMPA = 5 mice; black arrow indicates the day of xenograft implantation, purple arrow the day treatment started, purple line the
length of treatment, and continuous blue line that the treatment was daily). Graphs in L show mean ± SEM. ns, not significant (unpaired t test). P-value
in K was determined using the Gehan–Breslow–Wilcoxon test. (N) Waterfall plot of animals having single LNCaP-Ctrl xenografts on their flank (nNPS = 4;
nEnzalutamide + NPS = 6; NPS: mGluR group I antagonist NP S2390). Treatment was administered daily i.v. on day 24 after xenograft implantation (NPS: 1 mg/
kg; enzalutamide + NPS: 0.5 mg/kg enzalutamide and 1 mg/kg NPS). Inset shows a comparison between therapy with 2-PMPA (2-P) alone and 2-PMPA and
enzalutamide (E + 2-P). The graph depicts the corresponding data of Fig. 6 D, showing mean ± SEM. *, P < 0.05 (unpaired t test). (O) Inhibition of PSMA’s
carboxypeptidase activity with 2-PMPA impairs tumor growth in PSMA-expressing xenografts. Mice with either bilateral LNCaP-Ctrl or PC3-Ctrl xenografts
on both of their flanks were treated daily with vehicle (1× PBS) or PSMA inhibitor (20 mg/kg 2-PMPA) administered i.v. immediately after implantation of
the cells (n = 3 mice per cohort). Graph shows mean ± SEM. ns, not significant; ***, P < 0.001 (ordinary one-way ANOVA). (P) Treatment with 2-PMPA does
not impair tumor development in PSMA-null mice (C57BL/6J) implanted with Lewis lung carcinoma LL2 xenografts on their flank (nvehicle = 4; n2-PMPA = 6).
Vehicle (1× PBS) and 20 mg/kg 2-PMPA were administered daily i.v. immediately after the xenografts were implanted. Graph shows mean ± SEM. ns, not
significant (unpaired t test).
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Table S1. Expression of PSMA associates with biochemical recurrence in prostate cancer patients
Variables in the equation

PSMA expression Z >2
Biostats_nomogram_Stephanson

P

0.039
0

HR

2.658
0.961

95% CI for HR
Lower

Upper

1.049
0.947

6.739
0.974

Multivariate Cox regression (MSKCC prostate cancer patient cohort, PMID 25024180) of the correlation between PSMA expression and prostate cancer recurrence. BCR, biochemical recurrence; CI, confidence interval; HR, hazard ratio.

Table S2. Expression of PSMA associates with metastasis in prostate cancer patients
Variables in the equation

PSMA expression Z >2
Biostats_nomogram_Stephanson

P

0.019
0

HR

3.949
0.963

95% CI for HR
Lower

Upper

1.248
0.945

12.501
0.981

Multivariate Cox regression of association between PSMA expression and metastasis (MSKCC prostate cancer patient cohort PMID 25024180). CI, confidence interval; HR, hazard ratio.
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